Difference between Heparin and Enoxaparin on inflammatory biomarkers in the treatment of heart attack (myocardial infarction).

Recruiting

• Conditions: STEMI; inflammatory cytokin; Cardiovascular - Coronary heart disease; Inflammatory and Immune System - Other inflammatory or immune system disorders

• Registration Number: ACTRN12611001139965
• Lead Sponsor: Tehran university of medical science

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-11-01
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

age >18
patients with definite STEMI diagnosis

Exclusion Criteria

1-history of AMI or CHF or AF
2-history of liver( LFT> 3ULN), kidney(Cr>2 or Cr > 25% increase in baseline),thyroid disease or malignancy
3-acute or chronic infection or autoimmune disease
4- treatment with heparin or enoxaparin before study
5-pregnancy or breastfeeding
6-treatment with anti-inflammatory drug during 3 mounths ago

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
changes in inflammatory biomarkers (IL6, hs-CRP, MPO, SAA and ferritin) in plasma of STEMI pateints following anticuagolant therapy.[0,12,24,48 hours after starting administration of Heparin or Enoxaparin]

Secondary Outcome Measures

Name	Time	Method
il[Nil]